Form 4: Armata CBO Kyme Sells Shares for Tax Obligations

Armata Pharmaceuticals' Chief Business Officer, Pierre Kyme, reported the disposition of 1,030 common shares to cover tax liabilities related to restricted stock unit vesting.

Summary

• Pierre Kyme, Chief Business Officer of Armata Pharmaceuticals, Inc. (ARMP), reported a transaction on March 14, 2026.
• 1,030 shares of common stock were disposed of at a price of $10.54 per share.
• This disposition was a 'payment of tax liability by delivering or withholding securities incident to the receipt, exercise, or vesting of a security'.
• Following this transaction, Kyme beneficially owns 9,461 shares of Armata Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine tax-related transaction for equity compensation and not indicative of discretionary insider selling or buying.

Positives

• The transaction represents the vesting of restricted stock units, indicating a component of executive compensation is being realized.

Negatives

• A reduction of 1,030 shares from the Chief Business Officer's direct holdings, even if for tax purposes.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports a past insider transaction.

Industry Context

StockSavvy.ai notes that routine tax-related dispositions of shares following RSU vesting are common across industries for executives receiving equity compensation. This transaction does not reflect a discretionary sale based on market sentiment.

Comparison to Industry Standards

• This transaction is a standard practice for executives receiving equity compensation, where shares are withheld to cover tax obligations upon vesting of restricted stock units.
• It is consistent with compensation structures observed across various publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.

Related Party Transactions

• The withholding of shares by the company to satisfy income tax obligations related to restricted stock units is a standard practice for executive equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as it is a routine tax-related transaction, not a discretionary sale indicating a change in insider sentiment.
• Employees: Reflects the standard process for equity compensation vesting and tax handling.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by an insider to cover tax obligations related to restricted stock unit vesting. It does not provide new information regarding the company's operational performance, strategic direction, or the insider's discretionary view of the stock's future. Therefore, it offers no basis for a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Armata Pharmaceuticals, ARMP, Pierre Kyme, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, CBO